IP Library Granted Patent US 10,508,262
Granted Patent B1
US 10,508,262 · App. 16/160,006 · Granted Dec 17, 2019

Activation of immune cells

Inventor: Francis Christopher Zeigler (Carlsbad, CA)
Assignee: Breakthrough Tech LLC
C12N5/0634A61K35/17A61M1/008A61M2202/10A61M2205/7545C12N2501/90C12N2501/905
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,508,262
App. No.
16/160,006
Granted
Dec 17, 2019
Kind
B1
Abstract

Bone marrow containers are described herein. Separation systems for separating activated immune cells from other components are described herein. Methods of activating an immune cell are described herein.

Claims (15)

1. A method of activating immune cells of a subject, the method comprising:

obtaining bone marrow of the subject, the bone marrow comprising immune cells;

incubating the bone marrow with a non-ionic hydrophilic branched polysaccharide and a TLR2 ligand, wherein the non-ionic hydrophilic branched polysaccharide comprises poly(sucrose-co-epichlorhydrin),

wherein the non-ionic hydrophilic branched polysaccharide is at a concentration, wherein, if the bone marrow is contacted with whole blood and centrifuged, said concentration is sufficient to permit fluid movement of whole blood through the non-ionic hydrophilic branched polysaccharide without separation of erythrocytes,

wherein the non-ionic hydrophilic branched polysaccharide has a molecular weight greater than 20 kDa, and

wherein the incubating is performed until the immune cells are activated; and

administering the activated immune cells to the subject.

2. The method of claim 1 , further comprising identifying a subject as being in need of immune cell activation.

3. The method of claim 2 , wherein the subject has cancer.

4. The method of claim 3 , wherein the incubating further comprises incubating the hone marrow with a cancer cell antigen.

5. The method of claim 1 , wherein the non-ionic hydrophilic branched polysaccharide has a molecular weight of at least 70 kDa.

6. The method of claim 1 , wherein the concentration of the non-ionic hydrophilic branched polysaccharide is less than 1 gram per liter.

7. The method of claim 1 , wherein the concentration of the non-ionic hydrophilic branched polysaccharide is less than 1 grain per liter, and wherein the TLR2 ligand comprises hyaluronic acid.

8. The method of claim 1 , wherein the concentration of the non-ionic hydrophilic branched polysaccharide is less than 0.2 grams per liter, and wherein the TLR2 ligand comprises hyaluronic acid.

9. The method of claim 1 , wherein the method does not comprise leukapheresis.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 16, 2024
From: KNOBBE, MARTENS, OLSON & BEAR, LLP
To: BREAKTHROUGH THERAPEUTICS, LLC FKA BREAKTHROUGH TECH LLC
Reel/Frame 068601/0841 →
SECURITY INTEREST Recorded Sep 9, 2021
From: BREAKTHROUGH THERAPEUTICS, LLC FKA BREAKTHROUGH TECH LLC
To: KNOBBE, MARTENS, OLSON & BEAR, LLP
Reel/Frame 057454/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2019
From: ZEIGLER, FRANCIS CHRISTOPHER
To: BREAKTHROUGH TECH LLC
Reel/Frame 050880/0274 →
Continuity (1)
Provisional Application 62691775 · Jun 29, 2018